Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDP2939
- Development stage
- Phase 1
- Lead developer
- Evelo Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
EDP2939 is an orally delivered, investigational extracellular vesicle (EV) candidate that was developed by Evelo Biosciences. [2] It is manufactured from a single strain of the bacterium *Prevotella histicola*. [5, 8] The drug is designed to act on the small intestinal axis (SINTAX) to resolve inflammation. [2, 3] Its proposed mechanism involves acting in the small intestine to induce systemic regulatory T cells, which then modulate inflammation throughout the body. [5] EDP2939 was being evaluated for the treatment of moderate psoriasis. [2, 3] In October 2023, Evelo Biosciences announced that the Phase 2 clinical study of EDP2939 in moderate psoriasis did not meet its primary endpoint. [1, 3] Consequently, the company ceased the development of EDP2939 and initiated a process to explore strategic alternatives. [1, 4]
02
Targets
IL10RA (Interleukin-10 Receptor)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on EDP2939.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDP2939.